July 13, 2014 10:47 PM ET


Company Overview of Hoffmann-La Roche Inc.

Company Overview

Hoffmann-La Roche Inc., also known as Roche, operates as a research-focused healthcare company that discovers and develops diagnostic and therapeutic products for patients and healthcare professionals. The company offers drugs for various diseases, including cancer, viral infections, metabolic, central nervous system disorders, and inflammatory diseases, as well as pharmaceutical products for bioOncology, immunology and ophthalmology, metabolism and primary care, and virology and specialty care; and medical diagnostic products, such as diabetes care products, blood coagulation monitoring products, hospital and laboratory systems, research products, and point of care diagnostics portal. It al...

340 Kingsland Street

Nutley, NJ 07110

United States

Founded in 1905





Key Executives for Hoffmann-La Roche Inc.

Chief Executive Officer and President
Age: 59
Senior Principal Scientist of Respiratory Inflammation and Autoimmune Diseases
Global Head of Roche Pharma Partnering
Age: 55
Head of Roche Pharmaceuticals Western Europe Region
Age: 56
Business Development Director
Compensation as of Fiscal Year 2014.

Hoffmann-La Roche Inc. Key Developments

Hoffmann-La Roche Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 01:20 PM

Hoffmann-La Roche Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 01:20 PM. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Speakers: Bob Silverman.

Intas Pharma Signs Settlement and License Agreement with Roche for Xeloda

Intas Pharmaceuticals and its subsidiary Accord Healthcare Inc. announced that it has entered into a settlement and license agreement with Hoffmann-La Roche Inc. that will resolve pending patent litigation related to Xeloda Tablets, 150 mg and 500 mg, known generically as Capecitabine Tablets. This product is an orally administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Xeloda Tablets had U.S. sales of approximately $706.2 million for the 12 months ending Dec. 31, 2012, according to IMS Health. Intas reported that Hoffmann-La Roche Inc. had filed patent infringement suit against Accord Healthcare and Intas Pharmaceuticals following Accord's submission to the U.S. Food and Drug Administration of an Abbreviated New Drug Application (ANDA) for a generic version of Xeloda Tablets. As part of the agreement, the Company said that Hoffman La Roche Inc. has granted Accord a license to enter the U.S. market with a generic version of Xeloda Tablets ahead of its exclusivity period. Pursuant to the agreement, pending litigation would be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Hoffmann-La Roche Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 02:00 PM

Hoffmann-La Roche Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 02:00 PM. Venue: Westin Copley Place, Boston, Massachusetts, United States. Speakers: Kevin P. Anderson, PhD, Global Head, Virology Partnering.

Similar Private Companies By Industry

Company Name Region
Signature Therapeutics, Inc. United States
Aarden Pharmaceuticals, Inc. United States
Raritan Pharmaceuticals Inc. United States
AAIPharma Services Corp. United States
Shire Regenerative Medicine, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hoffmann-La Roche Inc., please visit www.rocheusa.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.